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Purpose: To explore changes in self-reported use of antacids over a 9-year period in a general population ad-
justed for changes in dyspeptic complaints. 
Methods: Data is based on two health surveys carried out in the same population in Norway in 1987-88 and 
1996-97. 15,523 individuals, who responded to the questions concerning drug use in either the first survey 
and/or in the second survey, were included in the analyses. Generalized estimating equation (GEE) was chosen 
for the multivariate analyses.  
Results: From 1987-88 to 1996-97 the proportion of antacid users in this region increased among men from 
11.2% to 12.7% (40-49 years) and from 11.9% to 13.4% (50-59 years), while the proportion of women using 
antacids decreased. The proportion of antacid users increased with age in both genders. In the same period, the 
frequency of self-reported dyspeptic complaints such as heartburn decreased. GEE analyses showed an overall 
increasing trend in antacid use over the 9 years (OR=2.0, 95% CI=1.8, 2.3) adjusted for self-reported heartburn 
and age. The effect of heartburn on antacid use is very strong (OR=14.6, 95% CI=12.9-16.7). The gender ef-
fect indicates that women are less likely to use antacids than men (OR=0.86, 95% CI= 0.77-0.95). Antacid use 
increased among those with dyspeptic complaints and also among those reporting no dyspeptic symptoms. 
Conclusion: The prevalence of antacid users in 1996-97 was higher than in 1987-88 adjusted for age, gender 
and heartburn. The proportion of antacid users increased among those with dyspeptic complaints and also 
among those reporting no dyspeptic symptoms.  






Antacids have been available for many years, and are 
still commonly used self-prescribed drugs1,2. However, 
their importance has diminished since the development 
of histamine-2-receptor antagonists and more recently 
proton pump inhibitors. Based on the drug wholesale 
statistics in Norway, the sale of antacids decreased 
from 7.6 DDD/1000 inhabitants/day in 1988 to 4.3 
DDD/1000 inhabitants/day in 19973,4. The histamine 
receptor antagonists (H2RA) and proton pump inhibi-
tors (PPI) have in the same period increased from 4.0 
DDD/1000 inhabitants/day (only H2RA) in 1988 to 5.2 
and 7.8 DDD/1000 inhabitants/day in 1997, H2RA and 
PPI, respectively. However, no information regarding 
drugs used at an individual level is available from the 
wholesale statistics. Although there are now drugs 
available that are more effective than antacids in 
healing ulcers and relieving the symptoms of gastro-
oesophageal reflux, many people still use over-the-
counter antacids in less severe forms of dyspepsia, es-
pecially those suffering from heartburn5-8. Dyspepsia 
is one of the commonest complaints in the community, 
usually including all symptoms referable to the upper 
gastrointestinal tract. The reported prevalence of dys-
pepsia varies to some extent depending on the defi-
nitions used and also on the period of time patients are 
under surveillance9-11. A reduction in the sale of anta-
cids may reflect various changes in individual drug 
use, i.e. decreasing number of users or smaller doses 
used. From a Norwegian health survey performed in 
1987-88 we have reported a prevalence of antacid use 
of about 10% in the general population12. Heartburn 
was the most important predictor for using antacids in 
both men and women. The survey was repeated in 
1996-97 in the same population thus offering the pos-
sibility of performing an analysis of the changes in use 
of antacids over time corrected for changes in dyspep-
tic complaints. In this paper we will explore the chan-
ges in the prevalence of self-reported use of antacids 
over a 9-year period in a general population. 
 
 
MATERIALS AND METHODS 
 
This study is based on data from two population-based 
health surveys carried out in the same population in 
the northernmost county of Norway in 1987-88 and 
1996-97. The health care system in the region is rela-
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tively uniform and almost exclusively public. Finan-
cial barriers with regard to the use of health services 
do not exist. 
 In the first health survey, 21,066 individuals aged 
20-62 years were invited to participate. This part of the 
survey was, to a large extent, a replication of two for-
mer health surveys performed in 1974-1975 and 1977-
78, respectively13,14. A detailed presentation of the ma-
terial and method of the full survey, including analyses 
of participants who did not answer all three question-
naires, has been published elsewhere12,15. Among those 
under 40 years a randomised sample was invited whilst 
all of those 40 years and older were invited to partici-
pate. 11,061 individuals who completed and returned a 
total of three questionnaires (52.5% of those invited) 
were included in the analyses (figure 1). The survey 
was repeated nine years later in 1996-97 in the same 
population where 12,366 individuals aged 20-71 years 
were invited to participate. 10,509 (85.0% of those 
invited) attended a physical examination and answered 
questionnaire 1. In addition 7,880 (63.7% of those in-
vited) answered also a second questionnaire (figure 1). 
All of those aged 40-42 years were invited, whilst a 
randomised sample was invited in the other age 
groups. 4,253 attended and answered the questions re-
garding use of drugs in both surveys. 
 One self-administered questionnaire (Questionnaire 
1) was part of the letter of invitation in both surveys, 
whereas supplementary questionnaires were handed 
out at the survey, and returned in pre-stamped en-
velopes. The questionnaires provided information on 
various aspects of health; health status, occurrence of 
different symptoms, self-reports of a number of disea-





Figure 1.  Flow chart for invited and attending individuals in 
the Finnmark Health Study 1987-88 and 1996-97. 
 In our study 15,523 individuals who responded to 
the questions concerning drug use in either the first 
survey and/or in the second survey, were included in 
the longitudinal analyses. The participants were asked 
if they had used any medication from different drug 
categories specified in the questionnaire assessing drug 
use. In this study the answer to the following question 
has been analysed (the same question was used in both 
surveys): “Have you taken antacids during the prece-
ding 14 days?” Individuals who answered “yes” to the 
question were defined as users. The others were defin-
ed as non-users. In the 1996-97 survey a new question 
on drug use was added: “Did you use other drugs for 
peptic ulcer?” 
 Participants in 1987-88 responded to the following 
questions about dyspeptic complaints (yes/no):  
• has acid regurgitation or heartburn bothered you? 
• have you been or are you bothered by pain in the 
upper abdomen? 
• have you had an ulcer in your stomach or 
duodenum?  
Participants in 1996-97 responded to the following 
three questions about dyspeptic complaints (yes/no):  
Have you in periods had: 
• pain located to the upper abdomen of at least 2 
weeks’ duration? 
• acid regurgitation or heartburn of at least 1 
weeks’ duration? 
Have you during the preceding 5 years been 
examined for peptic ulcer?  
Those who answered yes to one or more of the above 
three questions, including the question regarding pep-
tic ulcer, were defined as individuals with dyspeptic 
complaints. The others were defined as individuals 
with no complaints. 
 Both surveys included self-evaluated health, rated 
as excellent, good, fair or poor. Since heartburn was 
the strongest predictor for antacid use in the first sur-
vey, this variable was included in the multivariate ana-
lyses together with period, age and gender. Age is used 
as a continuous variable in the multivariate analyses. 
 
Statistical methods  
All statistical analyses were performed using the SAS 
statistical package, version 8.02. Differences between 
proportions were tested by chi square or chi square for 
trend as applicable. In epidemiology, longitudinal stu-
dies have been used in many situations, such as pros-
pective studies of exposure-disease relations, and 
repeated health services utilisation surveys. Analyses 
of repeated measures of data need to accommodate the 
statistical dependence among the repeated observa-
tions within individuals16. The generalized estimating 
equations (GEE) method of Liang and Zeger is com-
monly used to estimate population-averaged effects 
and is suitable for the analyses of repeated measures of 
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the dependency or correlation between the repeated 
measures by robust estimation of the variances of the 
regression coefficients19. While more complex than the 
traditional approaches, GEE use all available data and 
can produce more efficient estimates. By using GEE 
we can utilise the full potential of the longitudinal 
data. Consequently, the GEE method in the GENMOD 
procedure was chosen for the multivariate analyses. 
The working correlation was unstructured. A 0.05 le-
vel of significance was used for all the analyses. 
 The dependent variable is the repeated measure of 
using antacids at two time points, 1987-88 (T1) and 
1996-97 (T2). The independent variables include a 
period effect, the clinical variable heartburn, age and 
gender. The period effect implies the changes from T1 
to T2. We examined two models. The first model exa-
mined the association between use of antacids and 
period effect, heartburn, gender, and age. There was no 
significant interaction between period and age. How-
ever, significant interactions between period and heart-
burn, and between period and gender were identified. 
Therefore, the second model included four separate pe-
riod effects described by the interaction terms in addi-
tion to the main effects of age, gender and heartburn. 
To allow for different period effects depending on 
gender and heartburn, four interaction terms were con-
structed, representing the period effect on antacid use 
within each combination of gender and heartburn20. 
The effects of gender and heartburn are average effects 
over the two periods, thus having the same interpre-
tation as in the first model. The four period effects 
represented by the interaction variables are computed 
for individuals who do not change their heartburn sta-
tus from T1 to T2. 
 The GEE-analyses were done for both the 15,523 
participants and the 4,253 individuals that participated 
in both surveys and therefore had longitudinal data for 




Table 1 gives the proportion of antacid users stratified 
by gender and age. There was an increase in the pro-
portion of antacid users over the nine-year period for 
men from 11.2% to 12.7% (40-49 years) and from 
11.9% to 13.4% (50-59 years). There was, however, a 
weak decrease among women, from 9.3% to 8.8% (40-
49 years) and from 11.4% to 10.3% (50-59 years). The 
proportion of antacid users increased with age in both 
genders. 
 Table 2 is confined to individuals that participated 
and answered the drug use questions in both surveys. 
Eighty-two % of men and 80% of women reported no 
use of antacids at any time (p=0.07). 
 Table 3 gives the proportion of drug users accor-
ding to dyspeptic complaints. The proportion of anta-
cid users among those with no dyspeptic complaints 
increased from 1.5% to 4.0%. Among those with one 
or two dyspeptic complaints there was an increase in 
the proportion of antacid users, while among those 
with all three complaints there was practically no 
change in the proportion of antacid users. In the 1996-
97 survey, 146 (1.9%) individuals reported use of 
other drugs for peptic ulcer and the proportion of users 
increased with number of complaints (Table 3). 
Seventy individuals reported simultaneous use of 
antacids and other drugs for peptic ulcer. Fifty-nine of 
these had two or more dyspeptic complaints. 
 
 
Table 2. Use of antacids during the preceding 14 days among 
participants in both the Finnmark Health Survey 1987-88 
and 1996-97 (N=4,253). 
 
 Men Women 
Nonusers of antacids in both surveys 1789 (82.2%) 1662 (80.0%) 
Users of antacids only in 1996-97  152 (7.0%) 187 (9.0%) 
Users of antacids only in 1987-88  134 (6.2%) 115 (5.5%) 




Table 1.  Proportion of antacid users during the preceding 14 days according to age and gender. The 
Finnmark Health Survey 1987-88 (N=11,054) and 1996-97 (N=7859). 
 










group n % n %  
Age 
group n % n % 
20-39 924   9.7 1019   7.4  20-39   117   5.1   146   7.5 
40-49 2216 11.2 2044   9.3  40-49 1716 12.7 1834   8.8 
50-59 1821 11.9 1820 11.4  50-59   886 13.4   833 10.3 
60-62 598 13.2   612 13.1  60-69   805 13.7   840 12.3 
      70-71   300 14.3   382 14.4 
           
20-62 5559 11.4 5495 10.0  20-71 3824 12.9 4035 10.3 
           
  p (age trend) 0.02  <0.001    0.08  <0.001 
  p (gender) 0.02     <0.001  
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Table 3.  Proportion of antacid users and users of other peptic ulcer agents (%) during the preceding 14 
days according to number of dyspeptic complaints. The Finnmark Health Survey 1987-88 and 1996-97. 
 
1987-88 (N=11,061)  1996-97 (N=7,880) 
  
Antacid 
users   
Antacid 
users 
Users of other 
peptic ulcer agents 
 n %  n %  % 
No complaint 6388   1.5  5593   4.0   0.1 
One complaint 2549 14.0  1299 23.0   2.3 
Two complaints 1621 30.0    664 36.0   9.2 
Three complaints   503 46.0    324 44.0 15.4 




 In 1987-88, 42.2% reported one or more dyspeptic 
complaints while in 1996-97 only 29.0% reported at 
least one dyspeptic complaint. The prevalence of 
heartburn decreased from 37.6% to 20.3% and from 
33.3% to 20.0% in men and women, respectively. The 
prevalence of epigastric pain was reduced from 21.9% 
to 15.8% and from 22.6% to 18.7% in men and 
women, respectively. The prevalence of self-reported 
peptic ulcer increased in the same period from 10.4% 
to 14.6% and from 6.2% to 13.8% in men and women, 
respectively. Table 4 gives the proportion of antacid 
users during the preceding 14 days according to speci-
fic dyspeptic complaints and self-evaluated health, the 
1987-88 and the 1996-97 survey, respectively. The 
proportion of antacid users among those with com-
plaints of heartburn increased strongly from 26.4% to 
42.5% and from 25.9% to 40.7% in men and women, 
respectively. Among men not reporting heartburn, the 
proportion of antacid users also increased from 2.5% 
to 6.2%. However, among those with epigastric pain 
there was virtually no change in the proportion of 
antacid users. There were virtually no changes in self-
evaluated health from 1987-88 to 1996-97. Neither did 
the proportion of antacid users change according to 
self-evaluated health. 
 Table 5 shows the odds ratios for being an antacid 
user in two models. The period effect on antacid use 
gives an OR=2.0 at the second time point (reference is 
T1), indicating an overall increasing trend in antacid 
use. The effect of heartburn on antacid use is very 
strong, OR=14.2, showing that persons reporting 
heartburn are much more likely to use antacids than 
those not reporting heartburn. In addition, the odds ra-
tio of gender effect equals 0.86, indicating that women 
are less likely to use antacids than men. Age is signifi-
cant (p<0.001) in both models, indicating an increase 
in antacid use with increasing age independent of the 
period effect. In the model including interaction terms, 
the increase in antacid use among men without heart-
burn at any time gives OR=2.9 and among men with 
heartburn OR=2.0. The increase in antacid use among 
women without heartburn gives OR=2.0 and among 
women having heartburn at both time points OR=1.7. 
The GEE-analyses with the 4,253 individuals that at-
tended both surveys lead to nearly identical odds ratios 





From 1987-88 to 1996-97 the proportion of antacid 
users in this region increased among men from 11.2% 
to 12.7% (40-49 years) and from 11.9% to 13.4% (50-
59 years), while the proportion of women using anta-
cids decreased. The proportion of antacid users increa-
sed with age in both genders. In the same period, the 
frequency of self-reported dyspeptic complaints such 
as heartburn, which was the main predictor for antacid 
use, decreased. The GEE analyses showed an overall 
increasing trend in antacid use across the nine-year 
period, even when adjusted for self-reported heartburn 
and age. Antacid use increased among those with dys-
peptic complaints and also among those reporting no 
dyspeptic symptoms. This finding was consistent in 
both the bivariate and the multivariate analyses. 
 One main problem in this study as in longitudinal 
studies in general is missing data, i.e. when not all 
individuals have data at both or all time points. We 
therefore made GEE-analyses for both the total popu-
lation with missing data (N=15,523) and the popula-
tion where all individuals participated in both surveys 
(N=4,253). The analyses gave the same results and this 
indicates there was no selection by missing in our 
study, i.e. the missing data were ignorable. 
 
Antacid use  
One of the strengths in our study is that the questions 
about antacid use were not changed from 1987 to 
1996. There are, however, some limitations to this 
study. We had no information regarding doses, fre-
quency or duration of the antacid use i.e. the amount of 
antacid the individual user is exposed to, is not known. 
We do not, however, consider these limitations essen-
tial for interpreting the change of antacid use during 
the time period of our study. A nationwide health 
survey performed in Norway in 1995 reported that 8% 
used non-prescription drugs and 1.9% used prescrip-
tion drugs for dyspeptic symptoms, which is in accord-
ance with our findings21. Our results may indicate that 
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Table 4.  Proportion of antacid users during the preceding 14 days according to dyspeptic complaints 
and self-evaluated health. The Finnmark Health Survey 1987-88 and 1996-97. 
 
  Men  Women 
 Code n 
Antacid 
Users % p-value1 n 
Antacid 
users % p-value1 
   1987-88 (N=11,061)   
Heartburn 
   No 
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  1996-97 (N=7,854)   
Heartburn 
  No 
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Table 5.  Crude and adjusted odds ratio for being an antacid user estimated by generalized estimating equations. The period 
effect implies the changes from T1 to T2. The Finnmark Health Survey 1987-88 (T1) and 1996-97 (T2) (N=15,523). 
 
 Main effects of time, heartburn, and gender  
Adjusted model with four 
interaction terms 
 Crude odds ratio [95% CI] Adjusted odds ratio1 [95% CI]  Adjusted odds ratio [95% CI] 
Period (T1-T2) 1.43 [1.32-1.54] 2.03 [1.81-2.26]   
Heartburn   11.55 [10.23-13.03]   14.24 [12.58-16.13]    14.63 [12.85-16.66] 
Gender 0.83 [0.75-0.91] 0.86 [0.77-0.95]  0.86 [0.77-0.97] 
Age 1.02 [1.01-1.02] 1.01 [1.01-1.02]  1.01 [1.01-1.02] 
*Men without heartburn at both T1 and T2  2.94 [2.19-3.96] 
*Men with heartburn at both T1 and T2  2.02 [1.70-2.43] 
*Women without heartburn at both T1 and T2  2.03 [1.55-2.66] 
*Women with heartburn at both T1 and T2   1.73 [1.44-2.08] 
1 Odds ratio for period effects compares T2 to T1. Odds ratios for gender compare women to men and for heartburn yes to no. 
* Four interaction terms representing the period effect on antacid use within each combination of gender and heartburn. 
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the overall decrease of antacid drug use estimated from 
the wholesale statistics do not reflect a decline in the 
proportion of individual users. Another reasonable 
consideration to the decrease in the wholesale statistics 
is that lower doses of antacids have been used after the 
introduction of the histamine-2-receptor antagonists 
and proton pump inhibitors for dyspeptics with more 
severe symptoms. The unit of measurement in whole-
sale statistics is usually the Defined Daily Dose 
(DDD), which is defined as the assumed average 
maintenance dose per day for a drug use on its main 
indication in adults. The estimated drug consumption 
based on wholesale statistics is only valid if the drug is 
used regularly on a daily basis and there is good corre-
lation between the technical value DDD and the actual 
dose used. For drugs used intermittently in different 
doses, such as non-prescription antacids, wholesale 
statistics and DDD will not give an adequate estimate 
of the proportion of users in the population and the de-
velopment of antacid use in individuals over time22. 
 
Dyspeptic complaints  
Dyspeptic complaints were measured differently in the 
two surveys. In the 1996-97 survey the duration of the 
complaints, “at least 1 week’s duration” for heartburn 
and “at least 2 weeks’ duration” for epigastric pain, 
were added. This may have influenced the change in 
prevalence estimates as specifying an exact duration of 
the complaints may contribute to the decrease in the 
prevalence. The prevalence of the main predictor of 
antacid use, heartburn, went down from 38% to 20%. 
We do not know if this is a real change, or if it is due 
to the questions being different. Nevertheless we doubt 
that the differences in the questions could explain the 
whole decrease in prevalence. Our study revealed no 
change in the self-evaluated health and this may in-
dicate that the morbidity in this population did not 
increase in the period. In a health survey performed on 
the Norwegian population in 1995-97 the prevalence 
of heartburn or regurgitation during the past 12 months 
was 31%, which is higher than our figures from 1996-
9723. Other studies are showing that prevalence of dys-
pepsia varies from 15 to 40%, depending on the defi-
nition of dyspepsia and on the time frame of the preva-
lence11,24. The frequency and severity of dyspeptic 
symptoms were not incorporated in our study and 
therefore our figures may include individuals with 
trivial symptoms. 
 In summary, the traditional indication for antacid 
use is dyspepsia, and the strongest predictor of antacid 
use in our study at both cross-sections was heartburn. 
However, the longitudinal analyses showed that the 
increased prevalence of antacid users during this pe-
riod was not a consequence of increased frequency of 
the predictor of the antacid use. In fact, the increased 
proportion of antacid users tok place in dyspeptics as 
well as in non-dyspeptics. Thus we conclude that the 
increase in the prevalence of antacid users over the 
nine year period is not caused by the traditional indi-
cations for these medications. 
 
 
“TAKE HOME” MESSAGES 
 
• GEE analyses showed an overall increasing trend in 
antacid use over the 9-year period adjusted for self-
reported heartburn and age. 
• The gender effect indicates that women are less 
likely to use antacids than men. 
• There is an increase in antacid use with increasing 





The data collection was conducted in collaboration with the 
National Health Screening Services of Norway, now a part 
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